1. Pink Sheet
  2. >>Archive

FDA’s Guidance Document To-Do List Grows

 
• By Brenda Sandburg

Since releasing its annual guidance agenda in December, FDA has added a number of guidances to its development agenda.

FDA’s Center for Drug Evaluation and Research plans to publish 50 new or revised draft guidances in calendar year 2012. The agency recently posted the current list of forthcoming guidances on its website. CDER ticked off three major items on the list when it issued draft biosimilars guidances last month Also see "FDA Biosimilars Guidances Address Immunogenicity Studies, European Bridge Data, Analytics" - Pink Sheet, 13 February, 2012.. The agency plans to issue one more biosimilars guidance this year. Below are some of the key documents in the works, which were not included in the annual guidance agenda FDA published in a December Federal Register notice Also see "FDA’s Guidance Document To-Do List" - Pink Sheet, 3 January, 2011..

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet

‘Prices Can Remain Contaminated Indefinitely’: Advanz Brushed Aside On UK Liothyronine Appeal

 
• By Dean Rudge

England’s Court of Appeal has upheld a Competition Appeal Tribunal’s 2023 finding that Advanz and its former owner Cinven abused their dominant position in the UK market for liothyronine tablets by charging prices that were many orders of magnitude higher than the benchmark for fair pricing.

New EU Filings

 
• By Neena Brizmohun

Linerixibat, GSK's treatment for cholestatic pruritus in patients with primary biliary cholangitis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Podium Policy Returns To US FDA, Or Is It Podcast Policy?

 
• By Michael McCaughan

US FDA critics have long decried the practice of using informal communications to convey regulatory expectations as podium policy. In the Makary era, the phrase may need to be updated because the agency now seems to be specializing in policy by podcast.